Advertisement

Topics

Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes

09:00 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Ligand expects to report topline results in September 2017 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glu...

Other Sources for this Article

Ligand Pharmaceuticals Incorporated
Todd Pettingill, 858-550-7500
investors@ligand.com
@Ligand_LGND
or
LHA
Bruce Voss, 310-691-7100
bvoss@lhai.com

NEXT ARTICLE

More From BioPortfolio on "Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...